Neurology and Neurosurgery - Global Neurology Academy

Episodes 49-64 of 432

ASD in Children with SMA Type I: Diagnostic Challenges in a Multifactorial Context
ASD in Children with SMA Type I: Diagnostic Challenges in a Multifactorial Context
NeuroFrontiers
ASD in Children with SMA Type I: Diagnostic Challenges in a Multifactorial Context
Safety and Efficacy of Onasemnogene Abeparvovec in Pediatric SMA Across Expanded Weight Cohorts
Safety and Efficacy of Onasemnogene Abeparvovec in Pediatric SMA Across Expanded Weight Cohorts
NeuroFrontiers
Safety and Efficacy of Onasemnogene Abeparvovec in Pediatric SMA Across Expanded Weight Cohorts
New-Onset Ketosis-Prone Diabetes in an Adult with Spinal Muscular Atrophy Type III
New-Onset Ketosis-Prone Diabetes in an Adult with Spinal Muscular Atrophy Type III
NeuroFrontiers
New-Onset Ketosis-Prone Diabetes in an Adult with Spinal Muscular Atrophy Type III
Reevaluating Spinal Muscular Atrophy Therapy: Signs, Tools, and Strategies
Reevaluating Spinal Muscular Atrophy Therapy: Signs, Tools, and Strategies
NeuroFrontiers
Reevaluating Spinal Muscular Atrophy Therapy: Signs, Tools, and Strategies
- Brian P. McDonough, MD, FAAFP
- Nancy Kuntz, MD
Restoring Immune Balance: Low-Dose IL-2 Shows Promise in Alzheimer’s Research
Restoring Immune Balance: Low-Dose IL-2 Shows Promise in Alzheimer’s Research
NeuroFrontiers
Restoring Immune Balance: Low-Dose IL-2 Shows Promise in Alzheimer’s Research
Early Evidence Supports Videoconference ACT for Dementia Caregivers with Depression
Early Evidence Supports Videoconference ACT for Dementia Caregivers with Depression
NeuroFrontiers
Early Evidence Supports Videoconference ACT for Dementia Caregivers with Depression
Metabolic Modulation in Alzheimer’s Disease: Early Clinical Signals from a Dapagliflozin Pilot Trial
Metabolic Modulation in Alzheimer’s Disease: Early Clinical Signals from a Dapagliflozin Pilot Trial
NeuroFrontiers
Metabolic Modulation in Alzheimer’s Disease: Early Clinical Signals from a Dapagliflozin Pilot Trial
Rethinking Migraine Care: Prioritizing Patient Needs and Restoring Function
Rethinking Migraine Care: Prioritizing Patient Needs and Restoring Function
Global Neurology Academy
Rethinking Migraine Care: Prioritizing Patient Needs and Restoring Function
- Ashley Baker, MSN, PMHNP
- Stephanie Nahas, MD, MSEd
The Genetics of Migraine: Advancing Diagnosis and Personalizing Treatment
The Genetics of Migraine: Advancing Diagnosis and Personalizing Treatment
Global Neurology Academy
The Genetics of Migraine: Advancing Diagnosis and Personalizing Treatment
- Ryan Quigley
- Lyn R. Griffiths
Challenging Migraine Stereotypes: Improving Patient Care Through Empathy and Insight
Challenging Migraine Stereotypes: Improving Patient Care Through Empathy and Insight
Global Neurology Academy
Challenging Migraine Stereotypes: Improving Patient Care Through Empathy and Insight
- Charles Turck, PharmD, BCPS, BCCCP
- Rashmi B. Halker Singh, M.D.
Data Equity in Action: Largest Real-World MS Analysis Confirms Fumarate Efficacy Across Racial Groups
Data Equity in Action: Largest Real-World MS Analysis Confirms Fumarate Efficacy Across Racial Groups
NeuroFrontiers
Data Equity in Action: Largest Real-World MS Analysis Confirms Fumarate Efficacy Across Racial Groups
Intermittent Calorie Restriction Alters Immune and Metabolic Markers in RRMS
Intermittent Calorie Restriction Alters Immune and Metabolic Markers in RRMS
NeuroFrontiers
Intermittent Calorie Restriction Alters Immune and Metabolic Markers in RRMS
Early Ocrelizumab Intervention in RRMS: Real-World Data Reinforces a Shift in Strategy
Early Ocrelizumab Intervention in RRMS: Real-World Data Reinforces a Shift in Strategy
NeuroFrontiers
Early Ocrelizumab Intervention in RRMS: Real-World Data Reinforces a Shift in Strategy
Exploring Circulating CD34+ Cells as a Biomarker of Fracture Risk in DMD
Exploring Circulating CD34+ Cells as a Biomarker of Fracture Risk in DMD
NeuroFrontiers
Exploring Circulating CD34+ Cells as a Biomarker of Fracture Risk in DMD
Quantifying the Hidden Cost Burden of Duchenne Muscular Dystrophy on U.S. Households
Quantifying the Hidden Cost Burden of Duchenne Muscular Dystrophy on U.S. Households
NeuroFrontiers
Quantifying the Hidden Cost Burden of Duchenne Muscular Dystrophy on U.S. Households
Cardiopulmonary Exercise Testing Sheds Light on Early Physiologic Decline in Duchenne Muscular Dystrophy
Cardiopulmonary Exercise Testing Sheds Light on Early Physiologic Decline in Duchenne Muscular Dystrophy
NeuroFrontiers
Cardiopulmonary Exercise Testing Sheds Light on Early Physiologic Decline in Duchenne Muscular Dystrophy

4/9